Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs RestorLife Med

Claya
Graded #264

Lower grade

vs+2.5
RestorLife Med
Graded #222

Higher grade

The verdict

RestorLife Med takes it — 65.3/100 to 62.8/100.

RestorLife Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RestorLife Med is a physician-guided GLP-1 telehealth practice (founder Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRestorLife Med +2
42
44
Dose & formulationClaya +23
75
52
Clinical oversightRestorLife Med +15
82
97
Labs & monitoringRestorLife Med +13
53
66
FulfillmentRestorLife Med +30
67
97
Contract termsClaya +24
61
37
Claya · left barRestorLife Med · right bar

The numbers

MetricClayaRestorLife Med
WeighScore62.8/10065.3/100
GradeCC
Scorecard rank#264#222
Semaglutide$299/mo (compounded)$199/mo (6-month plan, compounded)
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #264 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
RestorLife Med

Graded #222 · C

Strengths

  • Verifiable LegitScript certification (seal ID 50400451) plus a named board-certified physician (Dr. Michael Wasef, MD) licensed in all 50 states
  • Full GLP-1 lineup: compounded semaglutide and tirzepatide, plus gentler microdose entry options
  • Generous support — unlimited care-team messaging, monthly check-ins, dosage adjustments, and 1 free blood test per quarter on the GLP-1 protocols
  • Available in all 50 states with free priority shipping, discreet packaging, and roughly 48-hour delivery
  • Transparent multi-month pricing with 50% off your first month; semaglutide protocols are compounded with B12

Where it loses points

  • The advertised $299 is a struck-through anchor price, not a starting point: the real month-to-month rate is $299, a first month runs $149 at 50% off, and the $199 rate needs six months
  • The page states its pricing is 'introductory and subject to change', so none of these figures is committed to
  • The tirzepatide price is published the same way, against a struck-through anchor, and we could not establish which figure a buyer actually pays
  • A separate semaglutide microdose is sold at $99/mo — a sub-therapeutic protocol, not a cheaper weight-loss dose
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard